| HOME >> BIOLOGY >> TECHNOLOGY |
The InQu Bone Graft Extender offers several advantages over existing synthetic bone graft substitutes including its unique ability to support the normal process of endochondral bone formation. It also eliminates the potential risk of infection that is common with allograft transplants.
ISTO Technologies has a team of committed scientists and staff working towards delivering high-quality orthobiologic products to the medical community. InQu has already won clearance from Food and Drug Administration (FDA) as a bone graft extender and substitute. The company has several InQu- related patents pending and intends to develop additional applications for the biomaterial technology in the near future.
"The company's development pipeline includes NuQu(TM), a cell-based injectable formulation of juvenile chondrocytes for nucleus regeneration of the spinal disc," notes Ishwarakrishnan. "In addition to this, the company is in clinical trials with DeNovo(R) ET, its scaffold-free living cartilage graft based on its patented cell based technology platform, to repair and regenerate damaged knee cartilage."
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in new products and technologies within its industry. The recipient company has shown innovation by launching a broad line of emerging products and technologies.
Frost & Sullivan's Best Practices Awards recognize companies in a
variety of regional and global markets for demonstrating outstanding
achievement and superior performance in areas such as leadership,
technological innovation, customer service, and strategic product
development. Industry analysts compare market participants and measure
performance thr
'/>"/>
| SOURCE Frost & Sullivan Copyright©2008 PR Newswire. All rights reserved |